Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of a Epratuzumab conjugated via a MC linker to a MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2E linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is targeted to certa...

  • Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2A linker to a SN-38.The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.The SN-38 is targeted to certain...

  • Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC

    Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4) conjugated via a AcBut linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediat...